Investment Thesis
Unicycive is a pre-commercial biotech with minimal revenue ($675K, declining -29% YoY) and severe cash burn ($6.2M quarterly operating loss) against only $37.4M in remaining cash, providing roughly 6 quarters of runway. The company exhibits extreme unprofitability (net margin -1899.7%) with no visible path to profitability or revenue acceleration, despite a strengthened balance sheet with zero debt.
Strengths
- No debt and strong liquidity position with current ratio of 2.40x reduces near-term refinancing risk
- Substantial cash reserves of $37.4M provide clinical development runway
- EPS improved 70.4% YoY, showing some operational progress despite absolute losses
Risks
- Accelerating cash burn of $6.2M quarterly with only ~6 quarters of runway remaining
- Severe revenue decline of -29% YoY indicates loss of pipeline momentum or failed commercialization
- Extreme negative profitability metrics (operating margin -1249.9%, net margin -1899.7%) with no clear path to breakeven
- Minimal revenue generation ($675K annually) inconsistent with commercial-stage biotech
- Zero insider Form 4 filings in past 90 days suggests lack of insider confidence
Key Metrics to Watch
- Quarterly cash burn rate and remaining runway (critical survival metric)
- Revenue growth trend reversal from current -29% YoY decline
- Operating loss magnitude and trajectory toward profitability
- Clinical trial advancement or regulatory milestone achievements (not in financial data)
Financial Metrics
Revenue
675.0K
Net Income
-12.8M
EPS (Diluted)
$-0.54
Free Cash Flow
-6.2M
Total Assets
64.4M
Cash
37.4M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-1,249.9%
Net Margin
-1,899.7%
ROE
-34.0%
ROA
-19.9%
FCF Margin
-925.8%
Balance Sheet & Liquidity
Current Ratio
2.40x
Quick Ratio
2.28x
Debt/Equity
0.00x
Debt/Assets
41.5%
Interest Coverage
-421.85x
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-15T10:18:06.213342 |
Data as of: 2026-03-31 |
Powered by Claude AI